9 studies found for:    19238148 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms
Condition: Neoplasm
Intervention: Drug: P276-00
2 Completed Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
Condition: Tumors
Intervention: Drug: SNS-032 Injection
3 Terminated A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer
Conditions: Neoplasms;   Lymphoma, Non-Hodgkin
Intervention: Drug: AG-024322
4 Completed AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma
Conditions: Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: CDKI AT7519;   Other: laboratory biomarker analysis
5 Completed Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
Conditions: B-lymphoid Malignancies;   Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma;   Multiple Myeloma
Intervention: Drug: SNS-032 Injection
6 Active, not recruiting A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Conditions: Neoplasms;   Lymphoma, Non-Hodgkin
Intervention: Drug: PD-0332991
7 Terminated Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: seliciclib;   Drug: placebo
8 Completed A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory Malignancies
Condition: Cancer
Intervention: Drug: P1446A-05
9 Completed A Study of R547 in Patients With Advanced Solid Tumors.
Condition: Neoplasms
Intervention: Drug: RG547

Indicates status has not been verified in more than two years